Wells Fargo raises BridgeBio Pharma stock price target on launch outlook
Wells Fargo raises BridgeBio Pharma stock price target on launch outlook Investing.com
Covered in this story
What has happened since
- Bridgebio Pharma Inc is down 18.6% since this was published, 72 days ago.
- Wells Fargo is down 5.1% since this was published, 72 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Bridgebio Pharma Inc
- Jefferies: $66.1 → $110 by Oct 2027 · Buy via Investing.com
- TD Cowen: $66.1 → $110 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BBIO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Bridgebio Pharma Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.